MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Aspirin on CTCs of Advanced Breast and Colorectal Cancer

Phase 2
Conditions
Epithelial-Mesenchymal Transition
Circulating Tumor Cells
Interventions
First Posted Date
2015-11-11
Last Posted Date
2015-11-13
Lead Sponsor
Zhejiang Provincial People's Hospital
Target Recruit Count
40
Registration Number
NCT02602938
Locations
🇨🇳

Zhejiang provincial people's hospital, Hangzhou, Zhejiang, China

Targeting Platelets in Chronic HIV Infection

Phase 2
Completed
Conditions
HIV-1 Infection
Interventions
First Posted Date
2015-10-19
Last Posted Date
2018-02-28
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
27
Registration Number
NCT02578706
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation

Phase 2
Completed
Conditions
Cerebral Hemorrhage
Atrial Fibrillation
Interventions
First Posted Date
2015-10-01
Last Posted Date
2021-04-14
Lead Sponsor
UMC Utrecht
Target Recruit Count
101
Registration Number
NCT02565693
Locations
🇳🇱

Haaglanden MC, Den Haag, Netherlands

🇳🇱

Leiden University Medical Center, Leiden, Netherlands

🇳🇱

Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands

and more 13 locations

Antiplatelet Therapy in HIV

Phase 2
Completed
Conditions
HIV
Cardiovascular Diseases
Inflammation
Interventions
First Posted Date
2015-09-24
Last Posted Date
2018-10-15
Lead Sponsor
NYU Langone Health
Target Recruit Count
55
Registration Number
NCT02559414
Locations
🇺🇸

Bellevue Hospital, New York, New York, United States

🇺🇸

NYU Langone Medical Center, New York, New York, United States

Pharmacodynamic Study of Cilostazol in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2015-09-18
Last Posted Date
2021-10-13
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
77
Registration Number
NCT02554721

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

Phase 4
Completed
Conditions
Diabetes Mellitus
Myocardial Infarction
Peripheral Arterial Disease
Interventions
First Posted Date
2015-09-14
Last Posted Date
2020-02-12
Lead Sponsor
University of Florida
Target Recruit Count
66
Registration Number
NCT02548650
Locations
🇺🇸

University of Florida, Jacksonville, Florida, United States

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Phase 4
Completed
Conditions
Myocardial Infarction
Interventions
First Posted Date
2015-09-10
Last Posted Date
2020-09-16
Lead Sponsor
University of Florida
Target Recruit Count
130
Registration Number
NCT02545933
Locations
🇺🇸

University of Florida, Jacksonville, Florida, United States

The Effects of COX-inhibiting Drugs on Skeletal Muscle Adaptations to Resistance Exercise in Healthy Adults

Phase 2
Completed
Conditions
Skeletal Muscle Mass Regulation
Interventions
First Posted Date
2015-08-24
Last Posted Date
2016-06-28
Lead Sponsor
Karolinska Institutet
Target Recruit Count
34
Registration Number
NCT02531451
Locations
🇸🇪

Karolinska Institutet, Stockholm, Sweden

Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Not Applicable
Completed
Conditions
Acute Myocardial Infarction
Interventions
First Posted Date
2015-08-24
Last Posted Date
2020-07-15
Lead Sponsor
Centre Hospitalier Universitaire Vaudois
Target Recruit Count
38
Registration Number
NCT02531165
Locations
🇨🇭

Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

Phase 2
Active, not recruiting
Conditions
Barrett Esophagus
Esophageal Adenocarcinoma
Interventions
Drug: Aspirin
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Other: Questionnaire Administration
First Posted Date
2015-08-13
Last Posted Date
2024-11-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
21
Registration Number
NCT02521285
Locations
🇺🇸

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

🇨🇦

Saint Michael's Hospital, Toronto, Ontario, Canada

🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

and more 7 locations
© Copyright 2025. All Rights Reserved by MedPath